Imagine your body's cells have little sugar tags on them that change when cancer appears. Instead of a painful needle biopsy, this test scans those sugar tags in a simple blood sample. It acts like a high-tech filter to spot the red flags of cancer early. This helps doctors decide who actually needs surgery and who is healthy.
Prostate cancer is the 2nd most frequent cancer in men, but current diagnostic paths often rely on invasive biopsies. This leads to high healthcare costs and patient discomfort, even for healthy individuals.
A non-invasive liquid biopsy test called ProSCAN that uses lectins to analyze glycan compositions in blood.
If you are a medical laboratory chain dealing with high demand for cancer screening — this project developed a glycan-based liquid biopsy that provides up to 90% accuracy. This allows you to offer a non-invasive alternative to traditional biopsies.
If you are a private hospital group dealing with the high cost of invasive procedures — this project developed ProSCAN to identify healthy men. This could help eliminate up to 1.6 million avoidable biopsies in the EU and US.
If you are an IVD manufacturer dealing with the need for next-generation screening tools — this project developed an ELISA-like assay using lectins to analyze glycans. This technology is applicable to 11 different types of cancer indications.
Based on available project data, the test could eliminate approximately 1.6 million avoidable biopsies, resulting in savings of about €1.5bn in the EU and US alone.
Yes, the project data states that this innovation is currently applicable to 11 types of cancer indications.
Based on available project data, the technology is developed by Glycanostics SRO, but specific licensing terms are not provided.
The project aims for a final accuracy of up to 90% for early-stage prostate cancer diagnostics.
The objective was to clinically validate and register ProSCAN as a non-invasive liquid biopsy test.
The project is led by a single Slovakian SME, Glycanostics SRO, indicating a highly concentrated IP ownership structure. With a 100% industry ratio and no university partners in the consortium, the project is driven by commercial application and market entry rather than basic research.
Contact GLYCANOSTICS SRO in Slovakia for licensing and validation data.
Contact us to explore integration of glycan-based diagnostics into your screening portfolio.
